This interview has been edited for length and clarity. JORGE GARAY: AI BioDesign seeks to explore possible molecules and biological functions that have never existed in nature. Are there any particular risks involved in venturing into this uncharted territory? How can scientists anticipate those risks and what steps can they take to minimize them before
tRNA in vitro production Oligonucleotides containing tRNA under a T7 promoter and followed by an HDV ribozyme61 were synthesized by IDT as high-fidelity DNA microchip oligo pools from 254–275 nucleotides in length, and dsDNA was amplified in a single PCR reaction for each pool. These tRNA pools included 48 unique E. coli isoacceptor tRNAs with
Bashor, C. J., Hilton, I. B., Bandukwala, H., Smith, D. M. & Veiseh, O. Engineering the next generation of cell-based therapeutics. Nat. Rev. Drug Discov. 21, 655–675 (2022). Article CAS PubMed PubMed Central Google Scholar Zhou, Y. et al. A small and highly sensitive red/far-red optogenetic switch for applications in mammals. Nat. Biotechnol. 40, 262–272
RESEARCH HIGHLIGHT 04 August 2026 Modified baker’s yeast can produce a precursor for a drug that is usually derived from an endangered plant and its relatives. The endangered plant Sinopodophyllum hexandrum is among the sources of a precursor for two cancer therapies. Credit: Felis Images/Nature Picture Library Every year, millions of people take the drugs
